Cancer immunotherapy has transformed the treatment landscape for multiple malignancies; however, its clinical efficacy remains limited in many tumors due to ...

MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2SK), engineered to precisely deliver clinically ...

Colorectal cancer remains one of the leading causes of cancer-related mortality worldwide, largely due to metastasis and ...

Colorectal cancer (CRC) remains one of the most prevalent malignancies and a leading cause of cancer-related mortality worldwide. Beyond tumor-intrinsic ...

Cancer cells continuously interact with their surrounding microenvironment, critically influencing tumor development, metastasis, immune evasion, and therapy resistance. Metabolic reprogramming in ...

Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with ...

The tumor microenvironment (TME) is a complex and dynamic network consisting of tumor cells, immune cells, stromal cells, extracellular matrix (ECM), cytokines, and growth factors, all interacting to ...

Researchers at the Josep Carreras Leukaemia Research Institute propose a new view of cancer based on spatial hallmark ecosystems and its evolution during cancer progression. This conceptual framework ...

It is perhaps no surprise that preclinical cancer models that fail to consider the TME show limited success in therapeutic development. Subcutaneous cell line-derived xenograft (CDX) models, in which ...

India, March 19 -- Tech giant Microsoft has unveiled a new artificial intelligence model called GigaTIME, which could ...

Discover six prostate cancer companies advancing the next generation of therapies for all stages of the disease.